Stock Price
37.68
Daily Change
-0.20 -0.53%
Monthly
0.72%
Yearly
47.71%
Q3 Forecast
37.57

Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 3.01M 10.05M Dec/2024
Amgen USD 694M 29M Jun/2025
AstraZeneca USD 303M 126M Jun/2025
Bayer EUR 495M 89M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Cytokinetics USD 24.26M 1.32M Jun/2025
Eisai JPY 916M 174M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 9M 4M Jun/2025
Glaxosmithkline GBP 184M 5.95M Jun/2025
Incyte USD 594K 66K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
MacroGenics USD 802K 826K Jun/2025
Merck USD 305M 8M Jun/2025
Moderna USD 1000K 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
Sanofi EUR 62M 4.11M Jun/2025
Takeda JPY 107.16B 56.83B Jun/2025
Ultragenyx Pharmaceutical USD 14.04M 1.48M Jun/2025
Xencor USD 8.24M 422K Jun/2025